Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS5315 in Chronic Spontaneous Urticaria
NCT05335499Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TAS5315 in chronic spontaneous urticaria (CSU), sponsored by Taiho Pharmaceutical Co., Ltd.. Started Jun 2022; status: completed.
02
Drugs
TAS5315
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05335499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335499.